Kari Gleiser
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.
Keren Tzarfaty, Michael Mithoefer, Julie Holland
MDMA's therapeutic mechanism differs from classical psychedelics, showing potential for treating CNS disorders. Shulgin's 1970s research inspired exploration of modifying MDMA's structure and developing novel compounds for improved effects.
Matthew Baggott
Sandell and colleagues discuss the benefits and risks of experiential training in psychedelic therapy for therapists, including potential therapeutic and theoretical functions, as well as risks like dual relationships and
Emma Hapke, Daniel Rosenbaum
Judith Herman's insights on integrating psychedelic therapy with mindfulness to protect against harm from current systems are discussed in this exploration of trauma and healing.
Bruce Poulter, Marcela Ot’alora
Psychedelic-assisted therapy field emphasizes establishing trust, safety, and reputability through professional guidelines, standards, and certification systems. Session discusses current developments in certification requirements and supportive infrastructure.
Brigadier General (Ret) Stephe…, Natalie Gukasyan, Shannon Carlin, Will Van Derveer
Therapists and religious professionals discuss ethical considerations in using psychedelics with vulnerable individuals, emphasizing the need for integrity and accountability in the psychedelic profession.
Cedar Barstow, Jennifer C Jones
Internal Family Systems (IFS) therapy, developed over four decades, offers evidence-based techniques to guide clients towards Self, fostering inner clarity and compassion. IFS provides a safe and healing map for
Richard Schwartz
Speaker discusses underlying assumptions of psychedelic therapy and therapist's role, emphasizing presence in facilitating healing. Draws from personal experiences with MDMA, psilocybin, and ketamine research volunteers.
Norma Stevens
Stanford conducted the first trial of Magnesium-Ibogaine on Special Operations Forces Veterans with traumatic brain injury, showing significant functional improvements and high remission rates for comorbid psychiatric disorders. Further controlled
Nolan Williams